Supplementary Tables 2-13 from Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition

Supplementary Table 2: BT-TR1 versus BT474 RNA sequencing normalized gene expression Supplementary Table 3: BT-TR2 versus BT474 RNA sequencing normalized gene expression Supplementary Table 4: BT-TPR1 versus BT474 RNA sequencing normalized gene expression Supplementary Table 5: BT-TPR2 versus BT474 RNA sequencing normalized gene expression Supplementary Table 6: BT-TR1 versus BT474 positively enriched hallmark pathways. Supplementary Table 7: BT-TR2 versus BT474 positively enriched hallmark pathways. Supplementary Table 8: BT-TPR1 versus BT474 positively enriched hallmark pathways. Supplementary Table 9: BT-TPR2 versus BT474 positively enriched hallmark pathways. Supplementary Table 10: BT-TR1 versus BT474 negatively enriched hallmark pathways. Supplementary Table 11: BT-TR2 versus BT474 negatively enriched hallmark pathways. Supplementary Table 12: BT-TPR1 versus BT474 negatively enriched hallmark pathways. Supplementary Table 13: BT-TPR2 versus BT474 negatively enriched hallmark pathways.